Henry Ford Health has treated the first Michigan patient outside clinical trials with Roctavian, the newly approved gene therapy for severe hemophilia A.

Anifrolumab, a type I interferon receptor antagonist, is currently approved under the brand name Saphnelo ® for intravenous administration in the treatment of moderate to severe SLE. If approved, a ...

Beyond sexual health risks, chemsex is linked to serious mental health consequences influenced by how often, how intensely ...

The agent, first approved in December for biweekly subcutaneous injection for EGFR-mutated NSCLC, showed similar efficacy and safety when administered monthly.

Rybrevant Faspro is a subcutaneous co-formulation of amivantamab, a bispecific EGFR-directed and MET receptor-directed antibody, and hyaluronidase.

The therapy dosing provides clinical outcomes consistent with those of the earlier approved bi-weekly subcutaneous regimen.

The patient, who is in his 30s, got the one-time intravenous infusion at the Infusion and Chemotherapy Treatment Center at ...

ADMA Biologics is a U.S.-based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients ...

In the past few days, President Donald Trump has sparked renewed health concerns with his appearance at public events. From ...

The FDA granted breakthrough therapy designation to Rybrevant Faspro based on data from the phase 1b/2 OrigAMI-4 study (NCT06385080).

Backed by Wellington, Sanofi Ventures and a division of J.P. Morgan, Korsana Therapeutics is studying a treatment originally developed by hub-and-spoke biotech Paragon Therapeutics.

The FDA has approved Optune Pax for the treatment of adult patients with locally advanced pancreatic cancer alongside gemcitabine and nab-paclitaxel.